Zydus Cadila gets USFDA nod for Phentermine Hydrochloride orally disintegrating tablets

Phentermine Hydrochloride orally disintegrating tablets is used together with diet and exercise to treat obesity (overweight) in people with risk factors such as high blood pressure, high cholesterol or diabetes.

New Delhi: Drug firm Zydus Cadila has received approval from the US health regulator to market Phentermine Hydrochloride orally disintegrating tablets used for the treatment of obesity in the American market.

The company has received final approval from the United States Food and Drug Administration (USFDA) to market Phentermine Hydrochloride orally disintegrating tablets in strengths of 15 mg, 30 mg, and 37.5 mg, Zydus Cadila said in a statement.

Read Also: Zydus Cadila gets final USFDA nod to generic version of Diamox for injection

The drug will be produced at the group's formulations manufacturing facility at Moraiya in Ahmedabad, it added.

The product is used together with diet and exercise to treat obesity (overweight) in people with risk factors such as high blood pressure, high cholesterol or diabetes, Zydus Cadila said.

Read Also: Zydus Cadila announces phase III trials of Desidustat to treat non-dialysis anaemia

The group now has more than 120 approvals and so far filed over 300 abbreviated new drug applications (ANDAs) since the commencement of the filing process.